3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
16
Fallopian Tube Neoplasms
14
Sarcoma
5
Breast Neoplasms
5
Carcinoma, Ovarian Epithelial
4
Neoplasms
3
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Sarcoma, Ewing
2
Multi-centric Castleman's Disease
2
Hodgkin Disease
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Vaccinia
1
Uterine Cervical Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Rhabdomyosarcoma
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
1
Recurrence
1
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Cancer Recurrent
1
Osteosarcoma
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphadenopathy
1
Interventions
liposomal doxorubicin
1
fludarabine
1
dostarlimab
1
Paclitaxel
1
Nivolumab
1
Ipilimumab
1
Gemcitabine
1
Doxorubicin
1
Dexamethasone
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma, Clear Cell
×
liposomal doxorubicin
×
90 days
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled